Viewing Study NCT05435742



Ignite Creation Date: 2024-05-06 @ 5:48 PM
Last Modification Date: 2024-10-26 @ 2:36 PM
Study NCT ID: NCT05435742
Status: TERMINATED
Last Update Posted: 2024-04-12
First Post: 2022-06-14

Brief Title: SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy CIPN
Sponsor: Sonnet BioTherapeutics
Organization: Sonnet BioTherapeutics

Study Overview

Official Title: A Randomized Double-blind Placebo-controlled Phase 1b2a Study to Evaluate the Safety Tolerability and Efficacy of Repeated Subcutaneous Administration of SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy CIPN After the End of Chemotherapeutic Treatment
Status: TERMINATED
Status Verified Date: 2024-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Lack of Enrollment
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The study will be conducted in adult patients with Chemotherapy-induced Peripheral Neuropathy CIPN that has been persistent for at least 3 months following completion of chemotherapy A total of 60 patients will be enrolled in equal numbers of a placebo group and two different SON-080 dose groups Treatment period will be 12 weeks long and patients will be followed-up for an additional 12 weeks
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None